By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: FDA Accepts NDA for VIVUS’ Qnexa
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > FDA Accepts NDA for VIVUS’ Qnexa
BusinessPublic Health

FDA Accepts NDA for VIVUS’ Qnexa

PatrickDriscoll
PatrickDriscoll
Share
2 Min Read
SHARE

VIVUS, Inc., has announced that the FDA has accepted its new drug application for the company’s Qnexa, a phentermine/topiramate combination.  The low-dose, oral, controlled-release drug is designed to reduce appetite and increase satiety.

VIVUS, Inc., has announced that the FDA has accepted its new drug application for the company’s Qnexa, a phentermine/topiramate combination.  The low-dose, oral, controlled-release drug is designed to reduce appetite and increase satiety.  According to the company:

The NDA resubmission seeks approval for the treatment of obesity, including weight loss and maintenance of weight loss for obese patients (BMI > 30 kg/m2), or overweight patients (BMI > 27 kg/m2) with weight-related co-morbidities such as hypertension, type 2 diabetes, dyslipidemia, or central adiposity (abdominal obesity). The proposed labeling includes a contraindication for women of childbearing potential. The resubmission also includes a proposed Risk Evaluation and Mitigation Strategy (REMS).

If all goes well, the FDA could approve Qnexa as early as first quarter 2012.

The opportunity for obesity drugs remains an enormous untapped opportunity.  Even the spate of regulatory challenges to obesity drugs over the past year has not dampened the prospects.  With the number of satiety drugs, malabsorption drugs, appetite suppression drugs and combination drugs that will reach the market in the next few years, we project that the global obesity drug market will hit $3.4 billion by 2019.

More Read

Increasing Hospital Risks
Time to Buy That Pet
Using Social Media to Promote Your Healthcare Events
Alternative Quality Contract with Blue Cross Blue Shield of Massachusetts: A Model for ACOs?
Small Business Coalition Launches National Anti-Reform Effort

Source: MedMarket Diligence, LLC; Report #S835.

     

TAGGED:obesityQnexa
Share This Article
Facebook Copy Link Print
Share
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

The Overweight Obsession Continues–Wireless HapiFork That Tracks Your Food and “Fork to Face” Rate

January 11, 2013
price transparency
BusinessFinance

Price Transparency Brought Lower Costs, More Competition, Study Says

August 8, 2014
The door to a hospital
BusinesseHealthSocial Media

Optimizing Your Hospital’s Online Presence: Structure Your Website in Accordance with SEO Best Practices

March 2, 2016
medical billing
BusinessFinanceHospital Administration

How Patient Experience Will Affect Medical Billing

October 31, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?